Trials / Conditions / Adenovirus Infection

Adenovirus Infection

17 registered clinical trials studyying Adenovirus Infection — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock O NCT05101213	M.D. Anderson Cancer Center	Phase 1
Terminated	Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving S NCT05179057	AlloVir	Phase 3
Terminated	Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic C NCT05305040	AlloVir	Phase 2 / Phase 3
Recruiting	Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infection NCT04722029	Nationwide Children's Hospital	Phase 1 / Phase 2
Completed	Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic NCT04693637	AlloVir	Phase 2 / Phase 3
Active Not Recruiting	Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transpl NCT03475212	Pediatric Transplantation & Cellular Therapy Consortium	Phase 1 / Phase 2
Withdrawn	Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A) NCT02276820	AlloVir	Phase 1
Unknown	Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections NCT03159364	Shenzhen Geno-Immune Medical Institute	Phase 1 / Phase 2
Withdrawn	Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation NCT02702427	St. Anna Kinderkrebsforschung	Phase 1 / Phase 2
Recruiting	A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipi NCT02007356	University Hospital, Basel, Switzerland	Phase 2
Completed	Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infectio NCT02087306	Jazz Pharmaceuticals	Phase 3
Completed	Clinical Grade Adenovirus Specific T Cells for Immunotherapy After Allogeneic Stem Cell Transplantation (CTL-A NCT02851576	Central Hospital, Nancy, France	Phase 1 / Phase 2
Completed	Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) NCT01070797	Baylor College of Medicine	Phase 1
Completed	Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus NCT00880789	Baylor College of Medicine	Phase 1
Completed	Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) NCT00711035	Baylor College of Medicine	Phase 1 / Phase 2
Completed	Administration of Virus-Specific Cytotoxic T-Lymphocytes NCT00590083	Baylor College of Medicine	Phase 1
Available	TETRAVI Expanded Access Program NCT07104591	Baylor College of Medicine	—